| Literature DB >> 34201589 |
Wei-Yun Lai1, Yen-Jen Chen2,3, Alvin Kai-Xing Lee2,4, Yen-Hong Lin4,5, Yu-Wei Liu4, Ming-You Shie4,6,7.
Abstract
Worldwide, the number of bone fractures due to traumatic and accidental injuries is increasing exponentially. In fact, repairing critical large bone defects remains challenging due to a high risk of delayed union or even nonunion. Among the many bioceramics available for clinical use, calcium silicate-based (CS) bioceramics have gained popularity due to their good bioactivity and ability to stimulate cell behavior. In order to improve the shortcomings of 3D-printed ceramic scaffolds, which do not easily carry growth factors and do not provide good tissue regeneration effects, the aim of this study was to use a gelatin-coated 3D-printed magnesium-doped calcium silicate (MgCS) scaffold with genipin cross-linking for regulating degradation, improving mechanical properties, and enhancing osteogenesis behavior. In addition, we consider the effects of fibroblast growth factor-2 (FGF-2) loaded into an MgCS scaffold with and without gelatin coating. Furthermore, we cultured the human Wharton jelly-derived mesenchymal stem cells (WJMSC) on the scaffolds and observed the biocompatibility, alkaline phosphatase activity, and osteogenic-related markers. Finally, the in vivo performance was assessed using micro-CT and histological data that revealed that the hybrid bioscaffolds were able to further achieve more effective bone tissue regeneration than has been the case in the past. The above results demonstrated that this type of processing had great potential for future clinical applications and studies and can be used as a potential alternative for future bone tissue engineering research, as well as having good potential for clinical applications.Entities:
Keywords: 3D printing; fibroblast growth factor-2; gelatin; magnesium-doped calcium silicate; osteogenesis
Year: 2021 PMID: 34201589 PMCID: PMC8301337 DOI: 10.3390/biomedicines9070712
Source DB: PubMed Journal: Biomedicines ISSN: 2227-9059
Figure 1Contact angle of the gelatin-coated MgCS scaffolds.
Figure 2(A) X-ray diffractometry (XRD) and (B) Fourier-transform infrared spectrometer (FTIR) spectra of the gelatin-coated MgCS scaffold.
Figure 3Stress–strain curves of the gelatin-coated MgCS scaffolds.
Figure 4SEM images of the surfaces of the gelatin-coated MgCS scaffolds.
Figure 5(A) Weight loss profiles and (B) tensile strength of the gelatin-coated MgCS scaffolds.
Figure 6SEM images of hydroxyapatite precipitated on the gelatin-coated MgCS scaffolds after 0, 7, and 14 days of immersion in the culture medium. The white bar below dictates 1 µm.
Figure 7(A) Cell proliferation and (B) F-actin stain of WJMSC on the gelatin-coated MgCS scaffolds at various time points. The scale bar is 400 µm.
Figure 8(A) ALP; (B) BSP; (C) OC expression of WJMSC cultured on the gelatin-coated MgCS scaffolds at various time points. * indicates a significant difference (p < 0.05) when compared to G0. # indicates a significant difference (p < 0.05) when compared to G2.5.
Figure 9(A) Drug release profiles; (B) proliferation assay; (C) ALP expressions of WJMSC on the gelatin-coated MgCS scaffolds at different time points. * indicates a significant difference (p < 0.05) when compared to G0.
Figure 10(A) Micro-CT image of the bone defects; (B) the quantified bone volume/total volume (BV/TV); (C) micro-CT quantified trabecular thickness (Tb.Th) analysis at various time points. * indicates a significant difference (p < 0.05) when compared to G0. # indicates a significant difference (p < 0.05) when compared to G5.0. The scale bar is 2 mm.
Figure 11Hematoxylin-eosin (HE); Masson’s trichrome (MT); von Kossa (VK) histological analyses of the gelatin-coated MgCS scaffolds after implant into the bone defects for 4 and 8 weeks. The scale bar is 400 µm.